GCAC’s Bratter on building an international databank of medicinal cannabis patient efficacy information
June 1, 2018 – “At GCAC we are building an international databank of medicinal cannabis patient efficacy information, which will be used to power intelligent platforms providing better outcomes for patients and doctors, better data for producers and retailers and better information for regulators and policymakers, while doing so GCAC is maintaining data integrity by utilizing blockchain…” states Blaise Bratter, Strategic Relationships Manager for Global Cannabis Applications Corp. (CSE: APP | OTCQB: FUAPF), in a recent presentation at the 7th Annual InvestorIntel Summit – Buds, Batteries & Blockchain 2018.
Blaise Bratter: Hello Everyone. My name is Blaise. I am from Byron Bay in Australia; first a bit about me. I am the general manager of the Medical Cannabis Council, which is Australia’s peak industry representative body, which represents now about 70% of the industry in Australia and is moving into 6 new territories worldwide. We focus on lobbying, education and medical professionals and general industry networking and services. I am also the strategic relationships manager for Global Cannabis Applications Corp. or GCAC. GCAC is based in Vancouver, but we have people in offices all over the world. At GCAC we are building an international databank of medicinal cannabis patient efficacy information, which will be used to power intelligent platforms providing better outcomes for patients and doctors, better data for producers and retailers and better information for regulators and policymakers, while doing so GCAC is maintaining data integrity by utilizing blockchain and incentivizing platform use with cryptocurrency. I have been involved in the cannabis industry in Australia for about 2½ years, which is the length that the industry has been open there. I have got a background in engineering and spent about 7 years in offshore oil and gas extraction and several years in policy development in primary industries in Australia. Just a quick slide on forward-looking statements for those that can speed read. I am going to start with a story about the average potential medicinal cannabis patient, Jane. Jane is an active young woman in her thirties who works as a software engineer, likes the outdoors, is planning to raise a family. Jane also has epilepsy. As someone who has dealt with the condition her whole life, Jane is accustomed to maintaining control of her seizures. However, when her usual medication started to be less effective Jane confessed her concerns to a friend who suggested medicinal cannabis as a potential treatment. Jane had never considered this possibility, but when she tried to learn more about it she struggled to find trustworthy sources therefore she turned to her physician. Her physician told Jane that although the benefits of cannabis have bene discussed among doctors for quite a few years she herself had not seen any evidence from reputable studies showing the clinical benefits of cannabis. The doctor explained that as a practitioner and a scientist she liked to have solid evidence and clinical experience before she prescribed medication to her patients and therefore she would not prescribe cannabis to treat Jane’s epilepsy. Then Jane came across GCAC’s platform, CannaLife. She was intrigued enough to install it and actually familiarized herself with our Citizen Green community. She found many other epilepsy sufferers. This made her reconsider how cannabis might be used to treat her condition. Jane presented the platform to her physician, showing her the large database of anecdotal patient information as well as all the clinical research that backs that up. After reading through all this and the consumer testimonials and all the clinical research, the physician felt confident enough to prescribe Jane with the medicinal cannabis license using our other app, Prescriptii, as a guide…to access the complete presentation, click here
More information on GCAC, read:
Disclaimer: Global Cannabis Applications Corp. is an advertorial member of InvestorIntel Corp.